/logo-16545883420.png){kind=logo}
Shenogen Presents at the 105th AACR Annual Meeting
The 105th Annual Meeting of the American Association for Cancer Research (AACR) will be held April 5-9, 2014, in San Diego, California, USA. The theme this year is “Harnessing Breakthroughs, Targeting Cures”. Dr. Charlie Wang, co-founder & Chief Science Officer, and Dr. Jun Bao, Senior Vice President & Chief Business Officer, will attend the event on behalf of Shenogen Pharma Group. They will show a poster of Shenogen’s development, reflecting how discoveries in the lab are translated into treatments in a targeted and precise manner. Shenogen’s lead molecule is another example of Chinese medicine modernization after artemisinin.
About Shenogen
Shenogen Pharma Group is a drug discovery and development company based in Beijing, China that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is currently in Ph II clinical trial for treatment of advanced hepatocellular carcinoma.